Skip to main content
Premium Trial:

Request an Annual Quote

UC Health to Have Expanded Access to GeneDx Tests

NEW YORK (GenomeWeb) – Opko Health's GeneDx business today announced it has extended an existing relationship with the University of California.

A spokeswoman with GeneDx said that one medical center in the UC Health network previously had been working with the firm, and the extension means that all five of the university system's medical centers plus its affiliates, will now work with GeneDx.

"The contract formalizes the relationship and essentially gives them license to send more [work] and track physician utilization to ensure that the right test is ordered at the right time," she said in an email. UC Health will have access to more than 400 tests for rare hereditary disorders, she added.

Financial and other terms of the deal were not disclosed.

In a statement Gregory Henderson, president of BioReference Laboratories, of which GeneDx is a business unit, said "[w]hole-exome sequencing and other clinical services offered by GeneDx will give UC Health's world-class doctors, genetic counselors, and other clinicians actionable insight into some of the most pressing health challenges faced by their patients." 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.